BBLG logo

Bone Biologics Corporation Stock Price

NasdaqCM:BBLG Community·US$3.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

BBLG Share Price Performance

US$2.00
-4.18 (-67.64%)
US$2.00
-4.18 (-67.64%)
Price US$2.00

BBLG Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with medium-low risk.

6 Risks
0 Rewards

Bone Biologics Corporation Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$3.9m

Other Expenses

-US$3.9m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-2.20
0%
0%
0%
View Full Analysis

About BBLG

Founded
2004
Employees
2
CEO
Jeffrey Frelick
WebsiteView website
www.bonebiologics.com

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company’s NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Recent BBLG News & Updates

Recent updates

No updates